From the Sant Pau Memory Unit (D.A., A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, IIB SANT PAU, Universitat Autònoma de Barcelona; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (D.A., A.L.), CIBERNED, Madrid, Spain; Department of Psychiatry (M.S.B.), Icahn School of Medicine at Mount Sinai, New York, NY; The Joseph Sagol Neuroscience (M.S.B., R.C.G.), Center Sheba Medical Center, Tel-Hashomer, Israel; and Department of Neurology (J.C.R.), Weill Institute for Neurosciences, UCSF Memory and Aging Center, San Francisco, CA.
Neurology. 2023 Jul 25;101(4):172-180. doi: 10.1212/WNL.0000000000207193. Epub 2023 Mar 6.
Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases. Currently, research studies have reported robust assays of blood markers for the detection of amyloid and tau pathologies specific to Alzheimer disease (amyloid-β peptides, and p-tau) and nonspecific blood markers of neuronal (neurofilament light, β-synuclein, and ubiquitin-C-terminal-hydrolase-L1) and glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiologic processes in several neurodegenerative diseases. In the near future, these markers may be used for screening, diagnosis, or disease and treatment response monitoring. Blood-based biomarkers for neurodegenerative diseases have been rapidly implemented in research, and they have the potential to enter clinical use soon in different clinical settings. In this review, we will describe the main developments and their potential implications for the general neurologist.
基于血液的生物标志物在神经退行性疾病的临床评估中取得了重大进展。目前，研究报告已经发现了针对阿尔茨海默病（淀粉样β肽和 p-tau）的淀粉样蛋白和 tau 病理的血液标志物以及神经元（神经丝轻链、β-突触核蛋白和泛素 C 端水解酶 L1）和神经胶质变性（神经胶质纤维酸性蛋白）的非特异性血液标志物的可靠检测方法，这些标志物可以测量几种神经退行性疾病中的关键病理生理过程。在不久的将来，这些标志物可能用于筛选、诊断或疾病和治疗反应监测。用于神经退行性疾病的基于血液的生物标志物已经在研究中迅速实施，并且它们有可能在不同的临床环境中很快进入临床应用。在这篇综述中，我们将描述主要的进展及其对一般神经科医生的潜在影响。
